SCHEMBL7132809

SCHEMBL7132809

O=S1(=O)CC(S(=O)(=O)c2ccccc2)c2cc(OCCCO)ccc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC10A2 Q12908 3/20 0.37
KAT6A Q92794 1/20 0.35
PPARD Q03181 4/20 0.35
PDK2 Q15119 1/20 0.34
CA2 P00918 3/20 0.34
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
GAA P10253 1/20 0.33
PNLIP P16233 2/20 0.33
MYC P01106 2/20 0.33
PPARG P37231 1/20 0.32
CA5A P35218 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
P2RY12 Q9H244 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7130849 0.91 SLC10A2 (0.39) SLC10A2KAT6APPARDPDK2CA2
SCHEMBL7133298 0.90 KAT6A (0.37) SLC10A2KAT6APPARDCA2CA1
SCHEMBL7132803 0.89 KAT6A (0.35) KAT6APPARDPDK2GAAPNLIP
SCHEMBL7131499 0.88 SLC10A2 (0.43) SLC10A2KAT6ACA2CA1CA9
SCHEMBL7130925 0.88 ITGB3 (0.39) SLC10A2PDK2CA2CA1CA9
Hydrochloric Acid SCHEMBL7161197 0.87 ITGB3 (0.38) SLC10A2PDK2CA2CA1CA9
SCHEMBL7134428 0.86 CA1 (0.35) PPARDCA2CA1CA9GAA
SCHEMBL7157336 0.86 PPARD (0.34) KAT6APPARDPDK2CA2CA1
SCHEMBL7133773 0.85 PTPN7 (0.46)
SCHEMBL7689836 0.85 KDM4E (0.46) SLC10A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed
US-6555555-B1 Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis ONO PHARMACEUTICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US disclosed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO SLC10A2 2746/4885KAT6A 4261/4885PPARD 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.